Bioidentical Hormones: Sound Science Or Bad Medicine : Hearing Before the Special Committee on Aging, United States Senate, One Hundred Tenth Congress, First Session, Washington, DC, April 19, 2007, Volume 4
U.S. Government Printing Office, 2007 - Electronic government information - 248 pages
What people are saying - Write a review
We haven't found any reviews in the usual places.
Other editions - View all
active addition American analyses Association benefit bioidentical hormones blood boards body breast cancer cardiovascular disease cause Center claims clinical clinical trials Code combined Committee compared compounded drugs concerns consumers continue controlled death doctors dosage dose drugs early effects estradiol estrogen estrogen plus progestin evidence Federal findings forms fractures heart disease hormone therapy hospital important increased indicates individual Institute issue less levels Manson manufactured medications Medicine menopause myocardial infarction natural observational outcomes participants patients pharmaceutical pharmacists pharmacy compounding physicians placebo postmenopausal women practice preparation prescribed prescription prevention prior progesterone questions randomized rates received reduced regulation reported Research risk safety Senator Senator Smith Special standards statement stroke suggest symptoms term testing treat treatment trial University Wiley Protocol women Women's Health Initiative
Page 166 - Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II).
Page 7 - National Institutes of Health US Department of Health and Human Services For Release on Delivery Expected at 10:00 AM Thursday, June 30,2005 46 Introduction Mr.
Page 60 - Manson, JE, Hsia, J., Johnson, KC, Rossouw, JE, Assaf, AR, Lasser, N. L., Trevisan, M., Black, HR, Heckbert, SR, Detrano, R., Strickland, OL, Wong, ND, Crouse, JR, Stein, E., and Cushman, M.
Page 61 - Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women.
Page 233 - manufacture" means the production, preparation, propagation, compounding, or processing of a drug or other substance, either directly or indirectly or by extraction from substances of natural origin, or independently by means of chemical synthesis or by a combination of extraction and chemical synthesis, and includes any packaging or repackaging of...
Page 70 - Again, thank you for the opportunity to testify before you today. I would be pleased to answer any questions you have at this time.
Page 34 - Director of the Bureau of Consumer Protection of the Federal Trade Commission.
Page 61 - Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, Haskell W, Knopp R, Lowery M, Satterfield S, Schrott H, Vittinghoff E, Hunninghake D.